Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology

$1.14 -0.01 (-0.44%)

High $1.17	Low $1.13	Trades 1,304	Turnover $2,983,889	Volume 2,606,681
30 June 2023 at 4:10pm

If you were already registered, log in here.

Market Cap (13-Nov) $2,538,662,912 (333rd)	Close (30-Jun) $1.14 0 (0%)	Volume (30-Jun) 2,606,681	Shortsold (9-Nov) 93,269,774 (7.17%) (40th)
52w High $3.31	52w Low $1.74	P/E 454.55	EPS -0.07

Short Interest

ASIC data, 9 Nov 2026

% Shorted

7.17% 0.01

vs 7.18% prior report

Most Shorted Rank

40th

of 711 shorted ASX stocks

Peak Short

11.00%

Oct 2015

Days to Cover

28.4

at 50d avg vol

View full short position history →

	Subject
	MSB MSB Article: ASX tumbles to three-month low; ASX CHESS outage
	1 (current) 2 3
	MSB MSB Article: ASX plummets to six-week low in broad sell-off
	MSB MSB Article: ASX slips as tech declines; Mesoblast soars 47pc
	MSB MSB Article: Mesoblast surges on FDA ‘rare paediatric disease’ designation
	MSB MSB Article: ASX rebounds as Whitehaven, Mesoblast power up
	MSB MSB Article: ASX rebounds as Whitehaven, Mesoblast power up
	MSB MSB Article: Mesoblast taps Bell Potter for $98m equity raising
	MSB MSB Article: ASX closes higher but ends the week down 1pc
	MSB MSB Article: Mesoblast: the biotech that hasn’t – yet
	MSB MSB Article: ASX ends the session higher but posts first weekly loss in four
	MSB MSB Article: Mesoblast and Neuren offer new parables for biotech investment
	MSB MSB Ann: Change of Director's Interest Notice
	MSB MSB Ann: Mesoblast Director Appointed to Strategic Advisory Role
	MSB MSB Ann: MSB Reports Q3 Financial Results and Operational Highlights
	MSB MSB Ann: Third Quarter Results Presentation
	MSB MSB Ann: Third Quarter Financial Results on Form 6-K
	MSB MSB Ann: Mesoblast Third Quarter Financial Results Webcast
	MSB MSB Ann: Becoming a substantial holder
	MSB MSB Ann: Change in substantial holding
	MSB MSB Ann: Cleansing Notice
	MSB MSB Ann: Application for quotation of securities - MSB
	MSB MSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	MSB MSB Ann: Reinstatement to Official Quotation
	MSB MSB Ann: Proposed issue of securities - MSB
	MSB MSB Ann: Mesoblast Completes Private Placement
	MSB MSB Ann: Voluntary Suspension
	MSB MSB Article: Mesoblast rattles the tin for at least $37m, Bell Potter in tow
	MSB MSB Ann: Trading Halt
	MSB MSB Ann: Pause in Trading
	MSB MSB Article: ASX jumps 0.9pc in biggest daily jump in two months
	MSB MSB Article: ASX jumps 0.9pc in biggest daily jump in two months
	MSB MSB Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
	MSB MSB Ann: Appendix 3G and Appendix 3H
	MSB MSB Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
	MSB MSB Ann: Pause in Trading
	MSB MSB Ann: Prospectus for Warrants Related to Oaktree Facility
	MSB MSB Ann: DREAM HF Trial Published in JACC
	MSB MSB Ann: MSB Q2 Financial Results and Operational Highlights
	MSB MSB Ann: Second Quarter Results Presentation
	MSB MSB Ann: Half Yearly Report and Accounts
	MSB MSB Ann: Mesoblast Second Quarter Financial Results Webcast
	MSB MSB Ann: Remestemcel Clinical and Potency Studies Presented at Tandem
	MSB MSB Ann: FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP
	MSB MSB Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
	MSB MSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	MSB MSB Ann: Appendix 3G, Appendix 3H and Appendix 3Ys
	MSB MSB Ann: Biotech Showcase 2023 Presentation in San Francisco
	MSB MSB Article: Mesoblast receives $US30m debt extension
	MSB MSB Ann: Extension of Undrawn US$30 million Facility
	MSB MSB Ann: Proposed issue of securities - MSB

If you were already registered, log in here.

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

Telix Pharmaceuticals

TLX

Upcoming Floats (8)

MATRIX CRITICAL MINERALS LIMITED

MTX

SUPER MINERALS LTD

S88

MAVERICK URANIUM LIMITED

MAV

Fitgenes

ATW $7.5m raise

RIO DE ORO CORP LTD

RDO $30m raise

Adbri Ltd

ABC $5m raise

RAMSAY GENERALE DE SANTE SA

RGS

Gratifii

MBM

Top

End of Day Prices

Date	Close	Volume	Change
13-Nov	$1.93	2,543,962	-0.03 (1.28%)
12-Nov	$1.96	3,137,996	-0.07 (3.69%)
11-Nov	$2.03	1,587,374	-0.05 (2.40%)
10-Nov	$2.08	2,613,105	+0.04 (1.96%)
09-Nov	$2.04	2,285,102	+0.01 (0.49%)
06-Nov	$2.03	2,423,463	-0.14 (6.45%)
05-Nov	$2.17	2,953,496	+0.07 (3.33%)
04-Nov	$2.10	2,601,657	-0.06 (2.78%)
03-Nov	$2.16	1,560,746	0.00 (0.00%)
02-Nov	$2.16	4,396,629	-0.10 (4.42%)
30-Oct	$2.26	3,452,259	-0.06 (2.59%)
29-Oct	$2.32	13,592,793	+0.44 (23.40%)
28-Oct	$1.88	2,650,500	+0.02 (1.35%)
27-Oct	$1.86	3,071,957	+0.07 (3.92%)
26-Oct	$1.79	1,315,866	+0.01 (0.56%)
7 up, 7 down, and 1 flat days

Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology

Short Interest

Followers

Prices

Announcements

Similar Companies

Upcoming Floats (8)

End of Day Prices

Mesoblast Health Care Biopharmaceuticals Cancer Medicine Oncology

Short Interest

Followers

Prices

Announcements

Similar Companies

Upcoming Floats (8)

End of Day Prices

Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology